Claret Capital Partners has made an investment, through its Fund IV, of up to €28 million in Cinclus Pharma, a late‑stage clinical pharmaceutical company developing next‑generation treatments for gastric acid‑related diseases. 

The proceeds will enable an earlier start of the final stage of Cinclus Pharma’s Phase III clinical programme HEEALING 1. 

They will also contribute to funding the remaining development and pre-launch activities of the company’s lead asset, linaprazan glurate, toward market approval and commercialisation. 

Linaprazan glurate, a next-generation Potassium-Competitive Acid Blocker (P-CAB) prodrug, has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments such as proton pump inhibitors (PPI).  

GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases. 

“This funding enables us to move with higher speed through the final stage of our clinical programme, with the goal of achieving market approval in both the US and Europe. Our first Phase III study, HEEALING 1, remains on track and was fully financed prior to this agreement, with topline results expected in the second half of 2026. This new capital allows us to look beyond that milestone and focus entirely on the fastest possible route to the patients who need this next-generation treatment,” said Christer Ahlberg, CEO of Cinclus Pharma. 

Philip Treacy, Vice President at Claret Capital Partners added: “Cinclus Pharma’s lead asset – a next‑generation P‑CAB demonstrating superior acid control and compelling Phase II results in the most severe patients – has the potential to redefine treatment and set a new benchmark in this category. We believe Cinclus Pharma is uniquely positioned to deliver a best‑in‑class therapy, and we are proud to partner with the team at this pivotal moment.”